J&amp;J May End Stent Shortcomings With Guidant Buy
95065
Credit Suisse First Boston maintained &quot;neutral&quot; ratings on Guidant (nyse: GDT - news - people ) and Johnson &amp; Johnson (nyse: JNJ - news - people ), saying a near-term acquisition of the former by the latter values Guidant at $76.
177578
Even as the ink dries on Johnson &amp; Johnson&#39;s agreement to buy Guidant Corp. for $25.4 billion, it remains on the hunt for other companies that could bolster
249844
CHICAGO/PHILADELPHIA  - Health care and consumer  products maker Johnson & Johnson JNJ.N is in negotiations to  acquire medical-device maker Guidant Corp. GDT.N, sources  familiar with the situation said on Tuesday.
202527
Johnson &amp; Johnson has made a deal to buy Guidant Corp. a producer of medical equipment for patients with heart and circulatory illnesses, for $24 billion in stock and cash.
16804
Johnson &amp; Johnson Chief Executive Officer William Weldon plans to use the $25 billion purchase of defibrillator maker Guidant Corp.
97019
Johnson &amp; Johnson is in advanced negotiations to acquire Guidant, an Indianapolis-based medical device maker, for more than $24 billion, executives close to the talks said Monday.
148143
Johnson & Johnson JNJ.N has sued   Boston Scientific BSX.N and Abbott Laboratories Inc. ABT.N,   seeking at least $5.5 billion in damages related to J&J's   failed bid to acquire medical device maker Guidant Corp.
700319
U.S. blue chips closed higher on  Thursday, helped by gains in Johnson & Johnson JNJ.N after  its move to buy Guidant Corp. GDT.N, but Goldman Sachs Group  Inc. GS.N dragged the S&P 500 down having posted quarterly  revenues that disappointed Wall Street.
6925
Johnson &amp; Johnson (JNJ.N: Quote, Profile, Research) on Thursday said it does not see any significant antitrust roadblocks getting in the way of its $25.4 billion acquisition of medical device maker Guidant Corp.
329296
Stocks stalled at the open Tuesday as investors shrugged off the impact of weaker crude prices and reports that Johnson &amp; Johnson is seeking to buy Guidant in a $24 billion deal.
32462
Johnson &amp; Johnson, the US medical and consumer goods group, is in advanced discussions to buy Guidant, a maker of medical devices, in a deal that could be worth about $24bn (Â£12bn).
340737
Guidant Corp.&#39;s 10-year run as one of Indiana&#39;s most successful public companies will end with a $25 billion sale to health products giant Johnson &amp; Johnson.
213162
THE COMPANIES: Since being spun off by Eli Lilly and Co. in 1994, Indianapolis-based Guidant has become one of the world&#39;s top medical device makers by refining heart stents - tiny, mesh wire tubes that hold
173143
Johnson &amp; Johnson's drug-coated Cypher heart stent may be better than Boston Scientific's Taxus for repeat procedures to unclog some arteries, according to a study in the Jan. 12 Journal of the American Medical Association.
405260
Johnson &amp; Johnson is picking a price fight over drug-coated stents. Does Boston Scientific Corp. need to respond?
466964
NEW YORK Johnson &amp; Johnson is in advanced negotiations to acquire Guidant, one of the largest US makers of devices to treat heart and circulatory illnesses, according to executives close to the talks.
526354
Results of a study showing patients with acute heart attacks are more likely to die if given a drug-coated stent than a bare metal one are out of line with other findings, stent maker Johnson & Johnson said on Tuesday.